146 related articles for article (PubMed ID: 9823973)
1. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
[TBL] [Abstract][Full Text] [Related]
3. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.
Bentzen SM; Saunders MI; Dische S
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):372-81. PubMed ID: 12555876
[TBL] [Abstract][Full Text] [Related]
4. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
[TBL] [Abstract][Full Text] [Related]
5. Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study.
Hatton MQ; Hill R; Fenwick JD; Morgan SA; Wilson PC; Atherton PJ; Dickson J; Murray KE; Paul J
Radiother Oncol; 2016 Mar; 118(3):471-7. PubMed ID: 26687902
[TBL] [Abstract][Full Text] [Related]
6. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study.
Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK
J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
[TBL] [Abstract][Full Text] [Related]
8. Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy.
Bütof R; Löck S; Soliman M; Haase R; Perrin R; Richter C; Appold S; Krause M; Baumann M
Radiother Oncol; 2020 Feb; 143():44-50. PubMed ID: 31767470
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
Harney J; Goodchild K; Phillips H; Glynne-Jones R; Hoskin PJ; Saunders MI
Clin Oncol (R Coll Radiol); 2003 May; 15(3):109-14. PubMed ID: 12801046
[TBL] [Abstract][Full Text] [Related]
10. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.
Soliman M; Yaromina A; Appold S; Zips D; Reiffenstuhl C; Schreiber A; Thames HD; Krause M; Baumann M
Radiother Oncol; 2013 Mar; 106(3):299-304. PubMed ID: 23333018
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
12. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial.
Hechtner M; Krause M; König J; Appold S; Hornemann B; Singer S; Baumann M
Radiother Oncol; 2018 Feb; 126(2):283-290. PubMed ID: 29273262
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
[TBL] [Abstract][Full Text] [Related]
14. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
Saunders M; Dische S; Barrett A; Harvey A; Gibson D; Parmar M
Lancet; 1997 Jul; 350(9072):161-5. PubMed ID: 9250182
[TBL] [Abstract][Full Text] [Related]
15. [CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-call bronchial carcinoma].
Baumann M; Herrmann T; Matthiessen W; Koch R; Strelocke K; Paul U
Strahlenther Onkol; 1997 Dec; 173(12):663-7. PubMed ID: 9454350
[TBL] [Abstract][Full Text] [Related]
16. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
Saunders M; Dische S; Barrett A; Harvey A; Griffiths G; Palmar M
Radiother Oncol; 1999 Aug; 52(2):137-48. PubMed ID: 10577699
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of postoperative CHART and CHARTWEL in head and neck cancer.
Shah N; Saunders MI; Dische S
Clin Oncol (R Coll Radiol); 2000; 12(6):392-6. PubMed ID: 11202092
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
19. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
[TBL] [Abstract][Full Text] [Related]
20. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
Kepka L; Tyc-Szczepaniak D; Bujko K
J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
